We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novelion Therapeutics Inc | NASDAQ:NVLN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.68 | 0.63 | 0.6677 | 0 | 01:00:00 |
1
|
NAMES OF REPORTING PERSONS
Whitefort Capital Master Fund, LP
|
||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)
(a)
☐
(b)
☐
|
||
3
|
SEC USE ONLY
|
||
4
|
SOURCE OF FUNDS (see Instructions)
WC
|
||
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
☐
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
|
||
NUMBER OF
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7
|
SOLE VOTING POWER
0
|
|
8
|
SHARED VOTING POWER
1,886,230
|
||
9
|
SOLE DISPOSITIVE POWER
0
|
||
10
|
SHARED DISPOSITIVE POWER
1,886,230
|
||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,886,230
|
||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see Instructions)
☐
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.9%
|
||
14
|
TYPE OF REPORTING PERSON (see Instructions)
PN
|
1
|
NAMES OF REPORTING PERSONS
Joseph Kaplan
|
||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)
(a)
☐
(b)
☐
|
||
3
|
SEC USE ONLY
|
||
4
|
SOURCE OF FUNDS (see Instructions)
AF
|
||
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
☐
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
||
NUMBER OF
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7
|
SOLE VOTING POWER
0
|
|
8
|
SHARED VOTING POWER
1,886,230
|
||
0
|
SOLE DISPOSITIVE POWER
0
|
||
10
|
SHARED DISPOSITIVE POWER
1,886,230
|
||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,886,230
|
||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see Instructions)
☐
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.9%
|
||
14
|
TYPE OF REPORTING PERSON (see Instructions)
IN, HC
|
Item 3. |
Source and Amount of Funds or Other Consideration.
|
Item 5. |
Interest in Securities of the Issuer.
|
WHITEFORT CAPITAL MASTER FUND, LP
|
||
By: Whitefort Capital GP, LLC, its general partner
|
||
By:
|
/s/ David Salanic
|
|
David Salanic, Co-Managing Partner
|
||
By:
|
/s/ Joseph Kaplan
|
|
Joseph Kaplan, Co-Managing Partner
|
WHITEFORT CAPITAL MANAGEMENT, LP
|
||
By:
|
/s/ David Salanic
|
|
David Salanic, Co-Managing Partner
|
||
By:
|
/s/ Joseph Kaplan
|
|
Joseph Kaplan, Co-Managing Partner
|
/s/ David Salanic
|
|
DAVID SALANIC
|
/s/ Joseph Kaplan
|
|
JOSEPH KAPLAN
|
Date
|
Security
|
Amount of Shs. Bought/(Sold)
|
Approx. price ($) per Share
1
|
4/22/2019
|
Common Stock
|
31617
|
1.2905
|
5/3/2019
|
Common Stock
|
56290
|
1.2448
|
5/6//2019
|
Common Stock
|
33560
|
1.2434
|
5/7/2019
|
Common Stock
|
22422
|
1.266
|
5/22/2019
|
Common Stock
|
160000
|
0.88
|
1 Year Novelion Therapeutics Chart |
1 Month Novelion Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions